Transluminal Technologies was founded to create a true second-generation arterial puncture closure devices that directly address the shortcomings in currently-offered products related to ease-of-use, thereby accelerating adoption rates and fueling device sales. TTL contemplates selling its unique intellectual property to an existing cardiovascular device manufacturer following successful regulatory approvals.